Bullish Case: Bullish: A pivot to the BBB-ABC program or licensing deal could re-rate ALEC toward $4–$6 within 6–12 months. Small, asymmetric bets via low-cost long-dated calls align with the option surface; Helium AI forecasts +2.3%, and the return surface hints upside pockets at shorter horizons. SPY IV is elevated near term, signaling hedging demand. Catalysts from IND data or partnerships could unlock value; risk remains if data disappoints.

Bearish Case: Bearish: Ongoing pipeline risk, no near-term catalysts, and dilution pressure keep ALEC vulnerable; price could drift to $1–2 if data stay negative or financing need arises. The ALEC return surface leans negative over longer horizons and the SPY IV surface remains elevated, increasing hedging costs; Without catalysts (e.g., 2027 IND readouts), upside is uncertain. History suggests rangebound drift aligns with prior calls.

Potential Outcomes:

1. Clinical failure readout (40%): price drift lower.
2. Rangebound with dilution (30%): 1–3 price band persists.
3. Strategic deal/licensing (8%): possible re-rate to 4–6.
4. Bankruptcy/near-zero (12%): if cash runs out.
5. Positive surprise (5%): >100% rally on data.
6. Momentum spike (5%): short-term upside bursts.

May 20, 2026